Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 6, pp 23–26 | Cite as

Trimodale Behandlung als Alternative zur Zystektomie

Radiochemotherapie des Harnblasenkarzinoms

  • Cordula PetersenEmail author
  • Anastasia Löser
Schwerpunkt
  • 5 Downloads

Die multimodale, primär organerhaltende Therapie (TUR-B gefolgt von Radiochemotherapie, Salvage-Zystektomie bei invasivem Rest- oder Rezidivtumor) stellt eine Alternative zur radikalen Zystektomie mit kurativer Zielsetzung für Patienten mit einem muskelinvasiven Harnblasenkarzinom dar. Diese sog. „trimodale Therapie“ verbindet unterschiedliche Disziplinen. Lesen Sie hier über das eng abgestimmte Behandlungskonzept.

Literatur

  1. 1.
    Efstathiou JA et al. Longterm outcomes of selective bladder preservation by combinedmodality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705–11CrossRefGoogle Scholar
  2. 2.
    Krause FS et al. 15year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res. 2011;31(3):985–90PubMedGoogle Scholar
  3. 3.
    Mak RH et al. Longterm outcomes in patients with muscleinvasive bladder cancer after selective bladderpreserving combinedmodality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801–9CrossRefGoogle Scholar
  4. 4.
    Rödel C et al. Combinedmodality treatment and selective organ preservation in invasive bladder cancer: longterm results. J Clin Oncol. 2002;20(14):3061–71CrossRefGoogle Scholar
  5. 5.
    Ploussard G et al. Critical analysis of bladder sparing with trimodal therapy in muscleinvasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–37CrossRefGoogle Scholar
  6. 6.
    Milosevic M et al. Radiotherapy for bladder cancer. Urology, 2007. 69(1 Suppl):80–92CrossRefGoogle Scholar
  7. 7.
    Rödel C et al. Radiochemotherapie des Harnblasenkarzinoms. Onkologe. 2018;24(1):40–47CrossRefGoogle Scholar
  8. 8.
    Huddart RA et al. Randomized noninferiority trial of reduced highdose volume versus standard volume radiation therapy for muscleinvasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys. 2013;87(2):261–9.CrossRefGoogle Scholar
  9. 9.
    Søndergaard J et al. A comparison of morbidity following conformal versus intensitymodulated radiotherapy for urinary bladder cancer. Acta Oncol. 2014;53(10):1321–8CrossRefGoogle Scholar
  10. 10.
    James ND et al. Radiotherapy with or without chemotherapy in muscleinvasive bladder cancer. N Engl J Med. 2012;366(16):1477–88CrossRefGoogle Scholar
  11. 11.
    Mitin T et al. Transurethral surgery and twicedaily radiation plus paclitaxelcisplatin or fluorouracilcisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14(9):863–72CrossRefGoogle Scholar
  12. 12.
    Tester W et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996;14(1):119–26CrossRefGoogle Scholar
  13. 13.
    Shipley WU et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 8903. J Clin Oncol. 1998;16(11):3576–83CrossRefGoogle Scholar
  14. 14.
    Kaufman DS et al. Phase III RTOG study (9906) of patients with muscleinvasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twicedaily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7CrossRefGoogle Scholar
  15. 15.
    Coen JJ et al. Nomograms predicting response to therapy and outcomes after bladderpreserving trimodality therapy for muscleinvasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013;86(2):311–6CrossRefGoogle Scholar
  16. 16.
    Zietman AL et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on longterm survivors. J Urol. 2003;170(5):1772–6CrossRefGoogle Scholar
  17. 17.
    Lagrange JL et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97015). Int J Radiat Oncol Biol Phys. 2011;79(1):172–8CrossRefGoogle Scholar
  18. 18.
    Eswara JR et al. Complications and longterm results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012;187(2):463–8CrossRefGoogle Scholar
  19. 19.
    Bochner BH et al. Comparing Open Radical Cystectomy and Robotassisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol. 2015;67(6):1042–50CrossRefGoogle Scholar
  20. 20.
    Huddart RA et al. [SPARE Trial Management Group]. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int. 2010;106(6):753–5CrossRefGoogle Scholar
  21. 21.
    Vashistha V et al. Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2017;97(5):1002–20CrossRefGoogle Scholar
  22. 22.
    Seisen T et al. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017;72(4):483–7CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Strahlentherapie und RadioonkologieUniversitätsklinikum Hamburg-EppendorfHamburgDeutschland
  2. 2.Ambulanzzentrum, Bereich StrahlentherapieUniversitätsklinikum Hamburg-EppendorfHamburgDeutschland

Personalised recommendations